Bayer Pharmaceuticals Earns UK Approval for AMD Treatment

In the UK, Bayer Pharmaceuticals, based in Leverkusen, Germany, has earned approval from the National Institute for Health and Care Excellence for its Eylea as a wet age-related macular degeneration treatment, according to a report by thepharmaletter.

Advertisement

Eylea, aflibercept solution for injection, is only recommended if administered within the National Health Service and National Institute for Health and Care Excellence guidelines.

More Articles on Ophthalmology:
AAO Issues Statement on Pharmaceutical Compounding Legislation
BIOLASE Earns US Patent for Laser Technologies
Valeant Acquires Bausch + Lomb for $8.7B

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.